NOXXON Pharma N.V. announced entering into its second clinical collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, N.J. USA), to collaborate in the upcoming Phase 2 clinical trial of NOXXONs NOX-A12 in combination with MSDs anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as second-line therapy in pancreatic cancer. This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer. The vast majority of pancreatic cancer patients have microsatellite stable tumors which are resistant to checkpoint inhibitor monotherapy. The study will enroll up to 70 patients and will contain an interim go/no-go in each arm in addition to usual safety and efficacy endpoints. MSD will provide pembrolizumab and expert advice for the study protocol, while NOXXON will sponsor the trial that will be conducted in clinical centers in the US and Europe. The study will include two treatment arms to determine the most efficacious treatment combination to move forward into a registrational trial: Arm 1: NOX-A12 + pembrolizumab + gemcitabine + nab-paclitaxel; Arm 2: NOX-A12 + pembrolizumab + nano-liposomal irinotecan + 5-fluorouracil + leucovorin.